Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma

NCT02298595 is registered in ClinicalTrials.gov with Julie E. Bauman, MD, MPH as lead sponsor.

NCT NCT02298595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02298595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
Julie E. Bauman, MD, MPH
Phase
Phase 1/2
Overall status
Withdrawn
Start date
August 31, 2016
Completion date
August 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous, oropharyngeal cancer, oropharyngeal neoplasms, squamous cell carcinoma